Articles tagged "Malignancy"

2022 American Transplant Congress
Risk of Post-Transplant Lymphoproliferative Disease After Anti-Thymocyte Globulin in Childhood Solid-Organ Transplant Recipients
A. M. McKay¹, C. Teoh¹, J. Vasilevska-Ristovka², J. Browne², T. Banh², A. Dipchand¹, V. Ng¹, M. Solomon¹, U. Allen¹, Y. Avitzur¹, R. Parekh³
¹Transplant & Regenerative Medicine Centre, The Hospital for Sick Children, Toronto, ON, Canada, ²Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, ³Division of Nephrology, Department of Medicine, Women’s College Hospital and University Health Network, Toronto, ON, Canada
*Purpose: Determine if the use of anti-thymocyte globulin (ATG) in pediatric solid organ transplant recipients was associated with an increased risk of post-transplant lymphoproliferative disorder…
2022 American Transplant Congress
Risk of Tumor Recurrence, Functional Decline, and Metastatic Disease of Renal Transplant in Recipients with Hereditary Kidney Cancer: A Case Series
M. Antony, A. Chaurasia, N. Gopal, Z. Kozel, M. Linehan, M. Ball
Urologic Oncology Branch, National Cancer Institute, Bethesda, MD
*Purpose: Von Hippel-Lindau disease is a hereditary cancer syndrome characterized by bilateral, multifocal renal tumors and cysts. Advancements in nephron-sparing surgeries have improved functional and…
2022 American Transplant Congress
Kidney Transplantation in Patients Postradical Prostatectomy
S. Karhadkar, K. Wirshup, J. Kolansky, A. Gregor, J. Dawes, A. DiCarlo
Temple University Hospital, Philadelphia, PA
*Purpose: The population of the United States is aging. By the year 2050 those over 65 years of age are projected to make up 20.2%…
2022 American Transplant Congress
Donor-Derived Duodenal Adenocarcinoma of a Bladder-Drained Pancreas Allograft
D. Isaacson¹, J. Steggerda¹, Y. Xue¹, G. B. Auffenberg², N. N. Katariya³
¹Northwestern University, Chicago, IL, ²Urology of St. Louis, St. Louis, MO, ³Mayo Clinic, Phoenix, AZ
*Purpose: Donor-derived malignancies are rare but frequently present with aggressive pathology and high mortality rates [PMID 32627325]. The urologic literature demonstrates an increased risk of…
2022 American Transplant Congress
Characterizing the Landscape of Cancer Risk Following HLA-Incompatible Living Donor Kidney Transplantation
J. D. Motter¹, K. Jackson¹, K. Yu², R. M. Pfeiffer², A. Massie¹, J. Garonzik-Wang³, D. Segev¹, E. A. Engels²
¹Johns Hopkins University, Baltimore, MD, ²National Cancer Institute, Bethesda, MD, ³University of Wisconsin-Madison, Madison, WI
*Purpose: Incompatible living donor kidney transplant recipients (ILDKTr) require desensitization to facilitate transplantation across donor-specific antibody (DSA); however, this substantial upfront immunosuppression may result in…
2022 American Transplant Congress
Immunotherapy Before Solid Organ Transplantation: An International Transplant Community-Focused Survey
T. Ivanics¹, M. P. Claasen¹, D. Al-Adra², G. Sapisochin³
¹University of Toronto - University Health Network, Toronto, ON, Canada, ²Division of Transplantation, Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI, ³Multi-organ transplant program, University Health Network, Toronto, ON, Canada
*Purpose: The use of immunotherapy for cancer has increased and is expected to continue to grow. The outcomes after solid organ transplantation (SOT) in patients…
2022 American Transplant Congress
Association of Native Kidney Disease with De Novo Cancer Development After Kidney Transplant
Y. Caliskan¹, D. Axelrod², R. Li¹, W. Cheungpasitporn³, M. Schnitzler¹, M. McAdams DeMarco⁴, J. Ahn⁴, T. Alhamad⁵, H. Randall¹, S. Bae⁴, D. Segev⁴, K. L. Lentine¹
¹Saint Louis University, Saint Louis, MO, ²University of Iowa, Iowa City, IA, ³Mayo Clinic, Rochester, MN, ⁴John Hopkins University, Baltimore, MD, ⁵Washington University in Saint Louis, Saint Louis, MO
*Purpose: Primary glomerulonephritis (GN) and congenital anomalies of the kidney and urinary tract (CAKUT) have been shown to be associated with cancer development in the…
2022 American Transplant Congress
Treg Crosstalk with Both Tumor and Lymphatic Cells Promotes Metastasis Through Lta1b2-ltbr Signaling
W. Piao¹, R. S. Oakes², C. M. Jewell², J. Bromberg¹
¹Surgery, University of Maryland, Baltimore, MD, ²University of Maryland, College Park, MD
*Purpose: Lymphotoxin (LT) α1β2 high expressing Tregs are essential for immune tolerance although inhibiting antitumor immunity. Lymphatic endothelial cells (LEC) express the LT beta-receptor (LTβR),…
2022 American Transplant Congress
Ex Vivo Liver Resection and Autotransplantation – Should It Be Used More Frequently?
J. Weiner¹, A. Griesemer¹, A. Hemming², D. Levi³, T. Beduschi⁴, R. Matsumoto¹, A. Mathur¹, J. Emond¹, T. Kato¹
¹Columbia University Irving Medical Center, New York, NY, ²University of Iowa, Iowa City, IA, ³Atrium Health, Charlotte, NC, ⁴University of Florida, Gainesville, FL
*Purpose: Ex vivo liver resection expands the limits of resectability for advanced liver tumors but remains underutilized due to concerns about technical complexity and vascular…
2022 American Transplant Congress
Public Acceptance of Living Donor Liver Transplant for Colorectal Liver Metastases: A National Survey
E. Pope-Collins, M. Nickels, K. Dokus, J. Martens, E. Keller, R. Hernandez-Alejandro, B. Al-Judaibi
University of Rochester, Rochester, NY
*Purpose: Recent advancements in cancer treatment and post-transplant management have allowed for a wider population of living donor transplant candidates. We employed a national survey…

1
2
3
…
20
Next Page »